Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
11.95
-0.03 (-0.25%)
At close: Dec 5, 2025, 4:00 PM EST
11.93
-0.02 (-0.17%)
After-hours: Dec 5, 2025, 7:37 PM EST
Kura Oncology Employees
Kura Oncology had 192 employees as of December 31, 2024. The number of employees increased by 50 or 35.21% compared to the previous year.
Employees
192
Change (1Y)
50
Growth (1Y)
35.21%
Revenue / Employee
$541,818
Profits / Employee
-$1,129,604
Market Cap
1.04B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KURA News
- 1 day ago - Kura Oncology: A Cautious Buy - Seeking Alpha
- 2 days ago - Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 3 days ago - Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data - Seeking Alpha
- 3 days ago - First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - GlobeNewsWire
- 10 days ago - KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 16 days ago - Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript - Seeking Alpha
- 22 days ago - Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia - GlobeNewsWire
- 22 days ago - US FDA approves Kura Oncology's blood cancer therapy - Reuters